# NCT02105636 (NCT02105636)

> Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02105636
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Squamous Cell Carcinoma of the Head and Neck
- Interventions: Nivolumab; Cetuximab; Methotrexate; Docetaxel
- Enrollment: 361
- Primary outcome: Overall Survival (OS)

## Commentary we found

- Podcasts: 8
- YouTube: 5
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct02105636

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02105636", "email": "<work email>"}; the inbox owner confirms by the emailed link.